Pegasystems Insider: 4,478 RSUs Vest; 4,000 Shares Sold Under 10b5-1
Rhea-AI Filing Summary
Reporting person and role: Rifat Kerim Akgonul, Chief Product Officer of Pegasystems Inc. made multiple stock and restricted stock unit transactions in early September 2025.
On 09/05/2025 and 09/07/2025 Ms. Akgonul had restricted stock units vest and were converted into common shares (2,200 and 2,278 RSUs respectively). She acquired those vested shares (at $0 acquisition price) and her beneficial ownership rose to 75,819 shares at peak. Separate market sales executed under a pre-arranged Rule 10b5-1 plan occurred on 09/08/2025, disposing of 2,081 and 1,919 shares at weighted-average prices of $56.55 (range $55.95–$56.89) and $57.43 (range $57.15–$57.63), respectively, reducing holdings to 70,717 shares.
Positive
- RSU vesting disclosed with clear conversion into common shares (2,200 and 2,278 RSUs) showing compensation execution
- Sales executed under a Rule 10b5-1 plan adopted November 25, 2024, indicating pre-arranged and documented trading
- Weighted-average sale prices and ranges disclosed, with an undertaking to provide per-price breakdowns on request
Negative
- Net reduction in beneficial ownership from 75,819 to 70,717 shares following sales on 09/08/2025
- Material proceeds realized via sales (weighted-average prices $56.55 and $57.43) which reduced direct holdings
Insights
TL;DR: Insider received RSU vestings and executed pre-arranged sales under a 10b5-1 plan, causing modest net share reduction.
The filings show routine executive compensation events: restricted stock units vested and were converted into shares, increasing direct beneficial ownership before planned market sales reduced holdings. The sales were executed under a documented Rule 10b5-1 plan, with disclosed weighted-average sale prices and price ranges, which supports compliance and limits concerns about opportunistic trading. The net effect is a modest decline from 75,819 to 70,717 shares, indicating routine liquidity management rather than material stake changes.
TL;DR: Transactions appear procedural: RSU vesting and Rule 10b5-1 governed sales, which reduce but do not materially alter ownership.
The Form 4 details scheduled vesting terms and the 10b5-1 plan adoption date (November 25, 2024) used for sales on 09/08/2025. Vesting schedules described (25% at the date exercisable, remainder quarterly over three years) are standard. Disclosure of weighted-average sale prices and undertaking to provide per-price details on request enhances transparency. From a governance perspective, filings conform to Section 16 reporting expectations and show documented pre-clearance via a trading plan.
FAQ
What insider transactions did PEGA Chief Product Officer report on the Form 4?
Were the sales by the PEGA insider pre-arranged under a trading plan?
At what prices were the shares sold according to the Form 4?
How did these transactions affect the insider's holdings in PEGA?
What are the vesting terms disclosed for the RSU awards?